Trial Profile
A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Epirubicin (Primary) ; Autologous stem cell therapy; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PAD VS VCD Clinical Protocol
- 23 Jun 2013 New trial record